Enterprise Value
115.5B
Cash
5.524B
Avg Qtr Burn
N/A
Short % of Float
1.71%
Insider Ownership
0.11%
Institutional Own.
87.85%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tecartus® (brexucabtagene autoleucel) (CAR-T) Details B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia, Leukemia | Approved Quarterly sales | |
Yescarta® Details B-cell lymphoma, Lymphopenia | Approved Quarterly sales | |
Vemlidy (Tenofovir Alafenamide) Details Chronic hepatitis B | Approved Quarterly sales | |
Lenacapavir capsid inhibitor (GS-6207) Details Human immunodeficiency virus | Approved Quarterly sales | |
Veklury® (Remdesivir) Details COVID-19 | Approved Quarterly sales | |
Trodelvy® (sacituzumab govitecan-hziy) Details Breast cancer, ER+/HER2- breast cancer, Cancer | Approved Quarterly sales | |
Biktarvy Details Human immunodeficiency virus | Approved Quarterly sales | |
Seladelpar (MBX-8025) Details Primary biliary cholangitis, Non-alcoholic steatohepatitis , Primary sclerosing cholangitis, Liver disease | PDUFA Approval decision | |
Lenacapavir Details Human immunodeficiency virus | Phase 3 Data readout | |
Obeldesivir (GS-5245) Details COVID-19 | Phase 3 Update | |
Trodelvy® (sacituzumab govitecan-hziy; SG) Details Cancer, Urothelial cancer | Phase 3 Update | |
Anito-cel Details Multiple myeloma | Phase 3 Initiation | |
Sunlenca (Lenacapavir) Details Human immunodeficiency virus | Phase 2/3 Data readout | |
Bulevirtide (Hepcludex®) Details Hepatitis Delta Virus | Phase 2b Update | |
Sunlenca (Lenacapavir) + Islatravir Details Human immunodeficiency virus | Phase 2 Data readout | |
Etrumadenant Details Colorectal cancer | Phase 2 Update | |
Trodelvy® (sacituzumab govitecan-hziy) comb w/KEYTRUDA® Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Yescarta Details Lymphopenia, B-cell lymphoma | Phase 2 Update | |
Magrolimab+Azacitidine Details High risk myelodysplastic syndromes | Failed Discontinued |